RESEARCH MONOGRAPH · KDC-MN-311
Sulbutiamine
Sulbutiamine (Arcalion) is essentially two thiamine (vitamin B1) molecules joined by a disulfide bridge, developed in Japan in the 1960s. The dimerization makes the molecule fat-soluble enough to cross the blood-brain barrier readily, where regular thiamine struggles to penetrate. In the brain it is broken down to free thiamine, raising central thiamine levels and supporting the thiamine-dependent enzymes of glucose metabolism. Approved in France, Russia, and several Asian markets for asthenia (loosely, fatigue states). Used as a nootropic and anti-fatigue supplement. Clinical evidence is largely from older French and Russian trials of uneven quality. Tolerance can develop with daily use. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Synthetic disulfide thiamine derivative
A lipophilic disulfide thiamine analog that crosses the blood-brain barrier; developed in Japan for asthenia and used as a nootropic.
Abstract
Sulbutiamine (isobutyryl thiamine disulfide; CAS 3286-46-2; molecular formula C32H46N8O6S2; molecular weight 702.89) is a synthetic disulfide derivative of thiamine (vitamin B1) developed in Japan in the 1960s and approved in several Asian and European markets under the trade name Arcalion. The compound is structurally a dimer of two thiamine molecules joined by a disulfide bridge, conferring high lipophilicity and improved blood-brain barrier penetration compared to thiamine itself. Mechanism: thiamine prodrug; sulbutiamine is metabolized to thiamine in the brain, raising central thiamine concentrations and supporting thiamine-dependent enzymes (transketolase, pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase). Clinical use is in psychogenic asthenia and as a nootropic; evidence is from clinical trials with mixed methodology. Plasma half-life is approximately 5 hours. Used as a lipophilic thiamine prodrug in research and nootropic communities.
Mechanism of action
Disulfide thiamine prodrug; high blood-brain barrier penetration; supports thiamine-dependent enzymatic metabolism in brain.
Reported research dose ranges
Clinical 200 to 600 mg in the published literature.
References
- Tiev KP, et al. Sulbutiamine in adult asthenia: review of clinical trials. Sem Hop 2006.
- Lonsdale D. A review of the biochemistry, metabolism and clinical benefits of thiamin(e) and its derivatives. Evid Based Complement Alternat Med 2006.
- Bizot JC, et al. Sulbutiamine improves memory in animal models. Pharmacol Biochem Behav 2005.
Read the full monograph
The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.
The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.